Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
P Umaña, J Jean–Mairet, R Moudry, H Amstutz… - Nature …, 1999 - nature.com
The glycosylation pattern of chCE7, an antineuroblastoma chimeric IgG1, was engineered
in Chinese hamster ovary cells with tetracycline–regulated expression of β (1, 4)–N–…
in Chinese hamster ovary cells with tetracycline–regulated expression of β (1, 4)–N–…
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated …
CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin
lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal …
lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal …
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
…, WJ Greenleaf, C Klein, JJ Goronzy, P Umaña… - Nature, 2022 - nature.com
Combination therapy with PD-1 blockade and IL-2 is highly effective during chronic lymphocytic
choriomeningitis virus infection 1 . Here we examine the underlying basis for this synergy…
choriomeningitis virus infection 1 . Here we examine the underlying basis for this synergy…
Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose
…, A Ruf, AC Rufer, M Stihle, P Umaña… - Proceedings of the …, 2011 - National Acad Sciences
Antibody-mediated cellular cytotoxicity (ADCC), a key immune effector mechanism, relies
on the binding of antigen–antibody complexes to Fcγ receptors expressed on immune cells. …
on the binding of antigen–antibody complexes to Fcγ receptors expressed on immune cells. …
[HTML][HTML] The carbohydrate at FcγRIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms
…, F Stuart, P Sondermann, P Brünker, P Umaña - Journal of Biological …, 2006 - ASBMB
FcγRIIIa plays a prominent role in the elimination of tumor cells by antibody-based cancer
therapies. Non-fucosylated bisected IgGs bind this receptor with increased affinity and trigger …
therapies. Non-fucosylated bisected IgGs bind this receptor with increased affinity and trigger …
[HTML][HTML] Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell …
…, L Lundberg, D Perez-Callejo, P Umaña… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2: 1
structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I …
structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I …
A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors
…, C Jaeger, J Saro, V Karanikas, C Klein, P Umaña - Clinical Cancer …, 2016 - AACR
Purpose: CEA TCB is a novel IgG-based T-cell bispecific (TCB) antibody for the treatment of
CEA-expressing solid tumors currently in phase I clinical trials (NCT02324257). Its format …
CEA-expressing solid tumors currently in phase I clinical trials (NCT02324257). Its format …
[HTML][HTML] PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
Expansion and differentiation of antigen-experienced PD-1 + TCF-1 + stem-like CD8 + T cells
into effector cells is critical for the success of immunotherapies based on PD-1 blockade 1 , …
into effector cells is critical for the success of immunotherapies based on PD-1 blockade 1 , …
Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous …
…, T Suter, S Moser, U Püntener, P Umaña - Biotechnology and …, 2006 - Wiley Online Library
The effector functions elicited by IgG antibodies strongly depend on the carbohydrate moiety
linked to the Fc region of the protein. Therefore several approaches have been developed …
linked to the Fc region of the protein. Therefore several approaches have been developed …
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101
…, F Herting, A Plesa, T Friess, P Umana… - Molecular cancer …, 2011 - AACR
GA101 is a novel glycoengineered Type II CD20 monoclonal antibody. When compared
with rituximab, it mediates less complement-dependent cytotoxicity (CDC). As expected for a …
with rituximab, it mediates less complement-dependent cytotoxicity (CDC). As expected for a …